Beranda › Sistem Imun dan Gangguan › Massachusetts
Uji klinis Sistem Imun dan Gangguan di Massachusetts
10 studi untuk Sistem Imun dan Gangguan mencari peserta di lokasi di Massachusetts.
Kota di Massachusetts
Teks studi resmi (Bahasa Inggris)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07075185A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04104776A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Brigham and Women's Hospital, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Apr 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT06619561Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.